BRIDGEWATER, N.J., May 04, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that clinical data demonstrating that use of the V-Go® Wearable Insulin Delivery Device ...

Use of Regular Human Insulin could save U.S. patients with type 2 diabetes and healthcare systems thousands of dollars per patient annually BRIDGEWATER, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- ...

In older adults with type 2 diabetes, use of human regular insulin delivered by V-Go ® demonstrated similar glycemic control with no increased hypoglycemia risk compared to use of rapid acting insulin ...

BRIDGEWATER, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company which offers V-Go® Wearable Insulin Delivery device, a simple, all-in-one ...

BRIDGEWATER, N.J., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its ...

V-Go meets an adult Type 2 diabetes patient's insulin needs by providing a treatment that is simple, convenient and easy to use. V-Go mimics the insulin pattern of the body (when used according to the ...

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of therapeutic products ...

Afrezza revenue rose 23% to $18.49 million in the three months through the end of September, owing to higher prices and ...

* Valeritas V-GO wearable insulin delivery device provided significant and sustained A1C reductions and achieved a1c glycemic targets in patients with type 2 diabetes Source text for Eikon: Further ...

Deal includes $10 million USD upfront payment to Zealand and sales-based milestones Certain inventory related to V-Go ® and employees also included under the terms of the deal Agreement is part of ...